Efficacy and Tolerance of EGb 761® 120mg Two Times a Day on Dementia of Alzheimer Type's Onset in Patients Suffering From Memory Complaints. A Randomised, Double-blind, Multicentre, Parallel Groups, Placebo Controlled Phase IIIb/IV Study in Elderly Over 70

NCT00276510 Phase 4 COMPLETED

The purpose of this study is to determine whether Tanakan® is effective at slowing the progression from memory complaint to dementia of Alzheimer's type.

Details

Lead sponsor	Ipsen
Phase	Phase 4
Status	COMPLETED
Enrolment	2878
Start date	2002-02
Completion	2009-11

Conditions

• Memory Disorders, Age-Related
• Retention Disorders, Cognitive

Interventions

• EGb 761® (Tanakan®)
• Placebo

Primary outcomes

• EGb 761® efficacy on conversion rate of memory complaint to dementia of Alzheimer type by a survival analysis — Baseline, month 12, 24, 36, 48 and 60

Countries

France